Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma
Public ClinicalTrials.gov record NCT01774344. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study of Regorafenib in Patients With Hepatocellular Carcinoma (HCC) After Sorafenib
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The objective of this study was to evaluate efficacy and safety of regorafenib in patients with advanced liver cancer who had progressed after sorafenib treatment. Patients were treated with regorafenib or placebo using a 2:1 randomization scheme.
Study identification
- NCT ID
- NCT01774344
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 573 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 13, 2013
- Primary completion
- Feb 28, 2016
- Completion
- Jul 4, 2019
- Last update posted
- Aug 19, 2020
2013 – 2019
United States locations
- U.S. sites
- 17
- U.S. states
- 13
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Los Angeles | California | 90048 | — |
| Not listed | Los Angeles | California | 90095 | — |
| Not listed | Orange | California | 92868-3201 | — |
| Not listed | Aurora | Colorado | 80045 | — |
| Not listed | Washington D.C. | District of Columbia | 20007-2197 | — |
| Not listed | Gainesville | Florida | 32610-0286 | — |
| Not listed | Tampa | Florida | 33606 | — |
| Not listed | Chicago | Illinois | 60637 | — |
| Not listed | Louisville | Kentucky | 40202 | — |
| Not listed | Worcester | Massachusetts | 01655 | — |
| Not listed | Minneapolis | Minnesota | 55455 | — |
| Not listed | St Louis | Missouri | 63110 | — |
| Not listed | New York | New York | 10029 | — |
| Not listed | Rochester | New York | 14642 | — |
| Not listed | Pittsburgh | Pennsylvania | 15232 | — |
| Not listed | Richmond | Virginia | 23249 | — |
| Not listed | Seattle | Washington | 98101 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 130 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01774344, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 19, 2020 · Synced Sep 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01774344 live on ClinicalTrials.gov.